Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.62 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.62 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355076 | 0.92 | KMT2A (0.59) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23355086 | 0.90 | STS (0.59) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23379599 | 0.89 | MCOLN3 (0.53) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23355043 | 0.89 | MCOLN3 (0.50) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23379634 | 0.89 | KMT2A (0.54) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23379762 | 0.89 | TGFBR1 (0.52) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL23379770 | 0.87 | TGFBR1 (0.55) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL4513123 | 0.87 | NPY5R (0.48) | STS | |
| SCHEMBL23379772 | 0.86 | TGFBR1 (0.52) | MCOLN3MCOLN2MCOLN1TGFBR1STS | |
| SCHEMBL6603122 | 0.85 | GPR119 (0.46) | MCOLN3MCOLN2MCOLN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1368340-B1 | PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040092507-A1 | Melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092507-A1 | Melanocortin receptor agonists | MC1R, MC4R, MC5R | MCOLN3 182/4885MCOLN2 352/4885MCOLN1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.